

## **Autoantibodies in Diabetes Mellitus Type 1**

Insulin-dependent diabetes mellitus (IDDM) or type 1 diabetes mellitus (T1DM) is a T-cell mediated autoimmune disorder characterized by destruction of the pancreatic beta cells (Ziegler et al. 2013). Mostly starting in childhood, this leads to insulin deficiency and metabolic abnormalities, as impaired glucose homeostasis and symptomatic hyperglycemia (Pihoker et al. 2005). Patients require lifelong insulin treatment (Landin-Olsson et al. 1992).

In the 1970s it was described that beta cell destruction is associated with production of cytoplasmic autoantibodies to islet cells (ICAs) (Bottazzo *et al.* 1974). Using classic diagnostic ICA tests, polyclonal antibodies are detected in app. 85% of children with recently diagnosed T1DM (Winter *et al.* 2002).

In the early 1990s, new antigens were identified including 37/40 kDa tryptic fragments and the Glutamate decarboxylase (GAD) antigen (Borg *et al.* 1994; Passin *et al.* 1995).

GAD is a pyridoxal phosphate-dependent enzyme catalyzing irreversible decarboxylation of glutamate to form gamma-aminobutyrate (GABA). In humans, two genes encoding different GAD isoforms have been identified. Named according to their respective molecular weights, the pancreatic GAD65 isoform contains an N-terminal membrane-anchoring signal peptide and localizes in the proximity of the Golgi apparatus of islet cells and GABA-containing vesicles (Bu et al. 1992; Brilliant et al. 1990; Solimena et al. 1994). GAD65 autoantibodies appear in 70 – 80% of sera from recently diagnosed T1DM patients (Hagopian et al. 1993). However, they can also be present in nondiabetic individuals and are thus alone not strictly specific (Christie et al. 1994).

The 40 kDa antigen detected in 37/40 kDa tryptic fragments was considered to be another major target of autoimmune response in diabetes (Passin *et al.* 1995). The insulinoma-associated protein (IA-2), also called islet cell antigen 512 (ICA 512), is a catalytically inactive protein tyrosine phosphatase (PTP) (Bonifacio *et al.* 1995). It consists of an

Ordering Information			
13800 13801 13500 13501	Glutamate Decarb (GAD65) IA-2 (ICA 512)	noxylase 65 kDa	0.1 mg 1.0 mg 0.1 mg 1.0 mg

Printing scheme IA-2 pAb

HSA HSA C
GAD GAD GAD IA-2 IA-2 IA-2
C IgG IgG PS PS 1

PS 1

PS 2

BD 1

BD 2

Figure: Immunodot analyses of GAD65 and IA-2 in triplicates using a polyclonal IA-2 antibody (pAb), samples from T1DM patients (PS1-2) and blood donors (BD1-2). As positive (serum) controls, goat anti-human IgGMA (C) and IgG were used. As negative control HSA was spotted on nitrocellulose membrane.

N-terminal extracellular signal sequence, a transmembrane domain and a long C-terminal intracellular tail, that harbors the majority of autoantibody epitopes (Lampasona *et al.* 1996). Similar to GAD it is expressed within secretory granules in neural, neuroendocrine and pancreatic islet cells (Solimena *et al.* 1996). Compared to GAD antibodies, IA-2 antibodies appear later and are therefore used as predictive value for upcoming T1DM onset in at-risk individuals (Achenbach *et al.* 2013). IA-2 autoantibodies are detected in 60 - 80% of sera from individuals with recent onset of the disease (Winter *et al.* 2011).

DIARECT's antigens GAD65 and IA-2 (ICA512) are produced in the baculovirus/insect cell system.

## References:

Achenbach et al. (2013) Diabetologia. 56: 1615–1622 Bonifacio et al. (1995) J Immunol. 155(11): 5419-26 Bottazzo et al. (1974) Lancet. 2(7892):1279-83 Brilliant et al. (1990) Genomics. 6: 115-122 Bu et al. (1992) PNAS. 89: 2115-2119 Christie et al. (1994) Diabetes. 43: 1254-1259 Hagopian et al. (1993) Diabetes. 42: 631-636 Lampasona et al. (1996) J Immunol. 157: 2707–2711 Landin-Olsson et al. (1992) Diabetologia. 35: 1068-73 Passin et al. (1995) PNAS. 92: 9412-9416 Pihoker et al. (2005) Diabetes. 54: 52-61 Solimena et al. (1994) J Cell Biol. 126: 331-341 Solimena et al. (1996) EMBO J. 15: 2102-2114 Winter et al. (2002) Clinical Diabetes. 20 (4): 183-191 Winter et al. (2011) Clin Chem. 57: 168-175 Ziegler et al. (2013) JAMA. 309: 2473-2479

In some countries the use of certain antigens in diagnostic tests may be protected by patents. DIARECT is not responsible for the determination of these issues and suggests clarification prior to use.

180313\_Rev02









